Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Waist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Waist. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001404-37 Sponsor Protocol Number: CARDIO-REDUSE Start Date*: 2006-09-12
    Sponsor Name:Maastricht University
    Full Title: Cardiometabolic risk reduction by Rimonabant: the effectiveness in daily practice and its use
    Medical condition: Despite therapeutic advances, cardio metabolic disease still remains an important cause of death worldwide. The endocannabinoid system seems to be a new target for multiple risk factor management a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003797-25 Sponsor Protocol Number: GH100-013 Start Date*: 2005-12-09
    Sponsor Name:ConjuChem, Inc.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visc...
    Medical condition: Patients 18 to 65 years old with HIV-associated visceral obesity, on a stable antiviral regimen for at least 6 weeks, with a viral load ≤1,000 copies/mL and CD4 count ≥200 cells/mm3, a body mass in...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003426-24 Sponsor Protocol Number: CTU079G Start Date*: 2013-02-13
    Sponsor Name:Riemser Pharma GmbH
    Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004275-70 Sponsor Protocol Number: GPD-01-01 Start Date*: 2016-01-08
    Sponsor Name:Gene PreDiT SA
    Full Title: Influence of single nucleotide polymorphisms of carboxypeptidase D (CPD) gene on body weight and fat mass reduction by perindopril in obese subjects: A phase II, multicenter, double-blind study.
    Medical condition: Body weight and fat mass reduction by perindopril in obese subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005444-88 Sponsor Protocol Number: TH9507-CTR-1011 Start Date*: 2007-01-16
    Sponsor Name:Theratechnologies Inc.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A...
    Medical condition: HIV-associated lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024608 Lipodystrophy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000647-14 Sponsor Protocol Number: 15782601 Start Date*: 2016-05-23
    Sponsor Name:University Hospital Toulouse
    Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial
    Medical condition: Noonan syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003908-61 Sponsor Protocol Number: Vasc-UMCU-10B Start Date*: 2008-12-09
    Sponsor Name:University Medical Center Utrecht
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL A...
    Medical condition: Metabolic syndrome as defined by the ATP III criteria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010116-15 Sponsor Protocol Number: CTU 052 D Start Date*: 2010-05-31
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 40 kg/m² or diet-related obesity diagnosed by BMI of 27 to 40 kg/m² in patient with coexisting risk factors like hyperlipidaemia, type 2 diabetes mell...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002230-37 Sponsor Protocol Number: CLAF237ANL05T Start Date*: 2013-12-19
    Sponsor Name:Erasmus Medical Center
    Full Title: “Novel Approach to Detect the Detailed Effects of Vildagliptin on Beta-cell Dynamics in Patients with Early-onset Type 2 Diabetes”
    Medical condition: impaired fasting glucose/impaired glucose tolerance, prediabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000725-54 Sponsor Protocol Number: PIOc/LAN07/TIF Start Date*: 2006-09-29
    Sponsor Name:TAKEDA
    Full Title: Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin
    Medical condition: Type 2 diabetes and metabolic syndrome IDF definition
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022491 Insulin resistant diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004515-56 Sponsor Protocol Number: hepatology_MT_2007-08 Start Date*: 2008-04-28
    Sponsor Name:Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG
    Full Title: Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020018-27 Sponsor Protocol Number: Dbox2008/01978 Start Date*: 2012-04-19
    Sponsor Name:Tameside Hospital NHS Foundation Trust
    Full Title: Effect of Testosterone on endothelial function and Microcirculation in Type 2 Diabetic patients with Hypoganadism.
    Medical condition: Hypogonadism and erectile dysfunction in patients with type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003062-13 Sponsor Protocol Number: AZP01-CLI-003 Start Date*: 2020-02-25
    Sponsor Name:Millendo Therapeutics SAS
    Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005197-63 Sponsor Protocol Number: U1111-1128-8762 Start Date*: 2013-02-25
    Sponsor Name:Ana M. Wägner
    Full Title: Effect of liraglutide on physical performance: a randomised, double-blind, controlled study in patiens with type 2 diabetes.
    Medical condition: Patients with Diabetes type 2.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001080-24 Sponsor Protocol Number: NL76906.068.21 Start Date*: 2021-04-08
    Sponsor Name:Maastricht University
    Full Title: The effect of plant stanol ester consumption on the vaccination response to a COVID-19 vaccine
    Medical condition: COVID-19 vaccination respons of people with BMI 27-35 kg/m2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002600-18 Sponsor Protocol Number: 43/2007/O/Sper Start Date*: 2007-06-05
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: EVALUATION OF THE RELATIONSHIP BETWEEN INFLAMMATION-PHYSICAL ACTIVITY AND THE ACTIVITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
    Medical condition: Abdominal obesity with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052066 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006114-14 Sponsor Protocol Number: 62326B1658 Start Date*: 2012-04-17
    Sponsor Name:Research and Development department
    Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr...
    Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000440-10 Sponsor Protocol Number: CADPT02A12001 Start Date*: 2020-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and com...
    Medical condition: non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:12:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA